Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia

Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia

The flow cytometric detection of aberrant antigen expression is one method proposed for the quantification of minimal residual disease (MRD) in acute leukemias. The present study was designed to investigate the stability of the aberrant antigen expression at relapse or at treatment failure of initia...

Full description

Saved in:
Bibliographic Details
Published in:Cytometry (New York, N.Y.) Vol. 42; no. 4; pp. 247 - 253
Main Authors: Oelschlägel, Uta, Nowak, Ralf, Schaub, Annett, Köppel, Christine, Herbst, Regina, Mohr, Brigitte, Löffler, Christine, Range, Ursula, Günther, Heinrich, Aßmann, Michael, Siegert, Elke, Wendt, Elisabeth, Huhn, Renate, Bräutigam, Elisabeth, Ehninger, Gerhard
Format: Journal Article
Language:English
Published: New York John Wiley & Sons, Inc 15-08-2000
Subjects:
aberrant antigen expression
acute leukemia
Adult
Antigens, CD - metabolism
Antineoplastic Agents - therapeutic use
Bone Marrow - immunology
Bone Marrow - pathology
Child
Flow Cytometry
Humans
Immunophenotyping
Leukemia - drug therapy
Leukemia - immunology
Leukemia - pathology
Recurrence
Time Factors
Treatment Failure
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The flow cytometric detection of aberrant antigen expression is one method proposed for the quantification of minimal residual disease (MRD) in acute leukemias. The present study was designed to investigate the stability of the aberrant antigen expression at relapse or at treatment failure of initial chemotherapy. For this purpose, multiparameter immunophenotyping with a panel of 15 monoclonal antibodies was used at diagnosis as well as at relapse (43 patients with overall 65 aberrations) and at treatment failure (35 patients with overall 66 aberrations). There was a significant decrease in the percentage of the initially described aberrant antigen expression on leukemia blasts at relapse (P = 0.001; n = 65) as well as at treatment failure (P = 0.0001; n = 66) considering all aberrations in the whole leukemia population. Concerning only patients with acute myelogenous leukemia (AML), significant decreases in the aberrant expression could be detected at relapse (P = 0.031; n = 42) and at treatment failure (P = 0.0001; n = 52). The changes in patients with acute lymphoblastic leukemia (ALL) were significant only at relapse (P = 0.006; n = 23). Initially, the most informative aberration was not detectable in four patients at relapse and in seven patients at treatment failure. A decrease of under 50% of the initial value was observed in another 8 patients at relapse and in 10 patients at treatment failure. In further studies assessing the detection of aberrant antigen expression for MRD, quantification of the relapses should be explicitly analyzed regarding the persistence of the initially described aberrant antigen expression. Cytometry (Comm. Clin. Cytometry) 42:247–253, 2000. © 2000 Wiley‐Liss, Inc.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0196-4763
1097-0320
DOI:10.1002/1097-0320(20000815)42:4<247::AID-CYTO5>3.0.CO;2-V